Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
6.72
+0.05 (0.75%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Eupraxia Pharmaceuticals Market Cap
Eupraxia Pharmaceuticals has a market cap or net worth of $442.16 million as of August 14, 2026. Its market cap has increased by 126.02% in one year.
Market Cap
442.16M
Enterprise Value
335.84M
1-Year Change
126.02%
Ranking
Category
Stock Price
$6.72
ChartMarket Cap Chart
Since March 9, 2021, Eupraxia Pharmaceuticals's market cap has increased from $61.62M to $442.16M, an increase of 617.57%. That is a compound annual growth rate of 43.70%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 14, 2026 | 438.27M | 14.97% |
| Dec 31, 2025 | 381.21M | 241.41% |
| Dec 31, 2024 | 111.66M | 0.72% |
| Dec 29, 2023 | 110.86M | 90.37% |
| Dec 30, 2022 | 58.23M | 111.19% |
| Dec 31, 2021 | 27.57M | -55.25% |
| Mar 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ocugen | 457.80M |
| Ginkgo Bioworks Holdings | 457.24M |
| Puma Biotechnology | 455.81M |
| Larimar Therapeutics | 455.11M |
| Prothena Corporation | 454.85M |
| Q32 Bio | 451.01M |
| Inhibikase Therapeutics | 438.80M |
| Editas Medicine | 433.10M |